JP2016136950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016136950A5 JP2016136950A5 JP2016019841A JP2016019841A JP2016136950A5 JP 2016136950 A5 JP2016136950 A5 JP 2016136950A5 JP 2016019841 A JP2016019841 A JP 2016019841A JP 2016019841 A JP2016019841 A JP 2016019841A JP 2016136950 A5 JP2016136950 A5 JP 2016136950A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- seq
- nucleotide
- beta
- sequence according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 102
- 125000003729 nucleotide group Chemical group 0.000 claims 102
- 150000007523 nucleic acids Chemical group 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 229960005486 vaccine Drugs 0.000 claims 6
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 241001529453 unidentified herpesvirus Species 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000002255 vaccination Methods 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 208000024697 human cytomegalovirus infection Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 101150074007 UL99 gene Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 210000002845 virion Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10004751 | 2010-05-05 | ||
| EP10004751.3 | 2010-05-05 | ||
| EP10005045.9 | 2010-05-12 | ||
| EP10005045 | 2010-05-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508401A Division JP2013527758A (ja) | 2010-05-05 | 2011-05-05 | ベータヘルペスウイルス感染に対するワクチンおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016136950A JP2016136950A (ja) | 2016-08-04 |
| JP2016136950A5 true JP2016136950A5 (OSRAM) | 2016-09-23 |
| JP6427514B2 JP6427514B2 (ja) | 2018-11-21 |
Family
ID=44146744
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508401A Pending JP2013527758A (ja) | 2010-05-05 | 2011-05-05 | ベータヘルペスウイルス感染に対するワクチンおよびその使用 |
| JP2016019841A Active JP6427514B2 (ja) | 2010-05-05 | 2016-02-04 | ベータヘルペスウイルス感染に対するワクチンおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508401A Pending JP2013527758A (ja) | 2010-05-05 | 2011-05-05 | ベータヘルペスウイルス感染に対するワクチンおよびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9078867B2 (OSRAM) |
| EP (1) | EP2566957B8 (OSRAM) |
| JP (2) | JP2013527758A (OSRAM) |
| AU (1) | AU2011250191A1 (OSRAM) |
| CA (2) | CA2798214C (OSRAM) |
| ES (1) | ES2679245T3 (OSRAM) |
| SG (2) | SG185121A1 (OSRAM) |
| WO (1) | WO2011138040A2 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2793959C (en) * | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| TR201802741T4 (tr) | 2010-05-14 | 2018-03-21 | Univ Oregon Health & Science | Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları. |
| PT2691530T (pt) | 2011-06-10 | 2018-05-10 | Univ Oregon Health & Science | Glicoproteínas e vectores recombinantes cmv |
| EP2766385A2 (en) * | 2011-10-12 | 2014-08-20 | Novartis AG | Cmv antigens and uses thereof |
| US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| AU2014225886B2 (en) * | 2013-03-05 | 2020-04-16 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of T cell targeting |
| US20160243216A1 (en) | 2013-10-29 | 2016-08-25 | The University Of Sydney | Cmv immuno-stimulatory composition |
| CN113528466B (zh) | 2014-07-16 | 2024-12-24 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
| SG11201706454VA (en) | 2015-02-10 | 2017-09-28 | Univ Oregon Health & Science | Methods and compositions useful in generating non canonical cd8+ t cell responses |
| CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| BR112019007982A2 (pt) | 2016-10-18 | 2019-07-02 | Univ Oregon Health & Science | vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal |
| WO2020014222A2 (en) * | 2018-07-09 | 2020-01-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Viral promoters and compositions and methods of use thereof |
| US12276665B2 (en) | 2018-07-20 | 2025-04-15 | Aicuris Anti-Infective Cures Ag | Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses |
| WO2022072821A1 (en) * | 2020-10-02 | 2022-04-07 | Colorado State University Research Foundation | Compositions comprising inactivated microbes, and methods for use and production thereof |
| CN116042526B (zh) * | 2022-07-04 | 2023-11-10 | 北京肿瘤医院(北京大学肿瘤医院) | P16基因特异性甲基化的正常人永生化结肠成纤维细胞 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7374768B1 (en) | 1990-09-25 | 2008-05-20 | Xenova Research Limited | Viral vaccines |
| DE19733364A1 (de) * | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
| WO2000034497A2 (en) | 1998-12-09 | 2000-06-15 | The General Hospital Corporation | Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors |
| WO2005012545A2 (en) | 2003-07-25 | 2005-02-10 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors |
| EP2497831B1 (en) * | 2004-05-25 | 2014-07-16 | Oregon Health and Science University | TB vaccination using HCMV-based vaccine vectors |
-
2011
- 2011-05-05 SG SG2012080891A patent/SG185121A1/en unknown
- 2011-05-05 ES ES11718950.6T patent/ES2679245T3/es active Active
- 2011-05-05 WO PCT/EP2011/002252 patent/WO2011138040A2/en not_active Ceased
- 2011-05-05 EP EP11718950.6A patent/EP2566957B8/en active Active
- 2011-05-05 CA CA2798214A patent/CA2798214C/en active Active
- 2011-05-05 CA CA3128572A patent/CA3128572C/en active Active
- 2011-05-05 JP JP2013508401A patent/JP2013527758A/ja active Pending
- 2011-05-05 US US13/695,668 patent/US9078867B2/en active Active
- 2011-05-05 SG SG10201503450WA patent/SG10201503450WA/en unknown
- 2011-05-05 AU AU2011250191A patent/AU2011250191A1/en not_active Abandoned
-
2015
- 2015-06-09 US US14/734,415 patent/US20150306210A1/en not_active Abandoned
-
2016
- 2016-02-04 JP JP2016019841A patent/JP6427514B2/ja active Active
-
2018
- 2018-11-19 US US16/194,558 patent/US10842863B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016136950A5 (OSRAM) | ||
| Chavda et al. | Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world | |
| Martins et al. | Adjuvant-enhanced CD4 T cell responses are critical to durable vaccine immunity | |
| JP6890831B2 (ja) | Ｈｉｖ予備免疫化および免疫療法 | |
| JP2019526580A5 (OSRAM) | ||
| US20230293580A1 (en) | Sars-cov2-specific t cell compositions and their use in treating and preventing coronavirus and other respiratory virus infections | |
| Dong et al. | Incorporation of CD40 ligand or granulocyte-macrophage colony stimulating factor into Hantaan virus (HTNV) virus-like particles significantly enhances the long-term immunity potency against HTNV infection | |
| Bivas-Benita et al. | Airway CD8+ T cells induced by pulmonary DNA immunization mediate protective anti-viral immunity | |
| Lee et al. | Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus | |
| JP2017510262A (ja) | 組換え単純ヘルペスウィルス２（ｈｓｖ−２）ワクチンベクター | |
| JP2013527758A5 (OSRAM) | ||
| JP2013545448A5 (OSRAM) | ||
| Mohit et al. | Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections | |
| JP2019527676A5 (OSRAM) | ||
| Jindra et al. | Attenuated recombinant influenza A virus expressing HPV16 E6 and E7 as a novel therapeutic vaccine approach | |
| Johnson et al. | Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice | |
| Sereda et al. | Humoral and cell immune mechanisms under African swine fever | |
| Jiang et al. | HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-α | |
| Gonçalves et al. | Recombinant bovine IL17A acts as an adjuvant for bovine herpesvirus vaccine | |
| Naziri et al. | Antitumor effects of HPV DNA vaccine adjuvanted with beclin-1 as an autophagy inducer in a mice model | |
| Wong et al. | Sustained viremia suppression by SHIVSF162P3CN-recalled effector-memory CD8+ T cells after PD1-based vaccination | |
| Du et al. | Improvement in efficacy of DNA vaccine encoding HIV-1 Vif by LIGHT gene adjuvant | |
| Ngu et al. | Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells | |
| Adam et al. | A modified porous silicon microparticle promotes mucosal delivery of SARS-CoV-2 antigen and induction of potent and durable systemic and mucosal T helper 1 skewed protective immunity | |
| Pushparajah | Design of a DNA-Encoded Human Papilloma Virus-Like Particle Displaying a Vascular Endothelial Growth Factor Antagonistic Peptide for Characterization in Mammalian Cells |